Reply: The low responder according to the POSEIDON criteria: is the prognosis really poor?

Note: Funding Information: J.A.L. is supported by a Research Fellowship grant and received an unrestricted personal grant from Merck BV. H.L.T. received an unrestricted personal grant from Merck BV. F.J.M.B. received monetary compensation as a member of the external advisory board for Merck Serono (the Netherlands) and Ferring Pharmaceuticals BV (the Netherlands) for advisory work for Gedeon Richter (Belgium) and Roche Diagnostics on automated AMH assay development, and for a research cooperation with Ansh Labs (USA). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.